*
Winblad et al. 1999
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
Clinical
Improvement
0
12
24
36
52
Study Week 6 Months 1 Year
Clinical
Decline
Text Box: MMSE LS Mean Change from Baseline (+SE)
MMSE
LS Mean Change from
Baseline (+SE)
donepezil HCI
placebo
*p=0.0005
†p<0.05
‡p=0.001
‡
†
Donepezil vs placebo in a
1-year multinational clinical trial
Donepezil HCl significantly improved cognition vs placebo as measured by MMSE scores in a 1-year, multinational clinical trial.

• MMSE sores of ARICEPT® -treated patients in this 1-year, placebo-controlled clinical trial remained at or near baseline during a 1-year period.

• ARICEPT® produced statistically significant improvements vs placebo from Week 24 through Week 52.

• At Week 52, MMSE scores of patients receiving placebo had declied a mean of 2.2 points from baseline. This decline is consistent with the expected decline of 2 to 4 points in MMSE scores of untreated mild to moderate AD patients.